Potential drug-drug interactions in outpatient lung cancer patients in a university hospital

Basit Öğe Kaydı
dc.authoridCavdar, Eyyup/0000-0001-5885-3047
dc.contributor.authorDemirkapu, Mahluga Jafarova
dc.contributor.authorCavdar, Eyyup
dc.date.accessioned2024-10-29T17:58:47Z
dc.date.available2024-10-29T17:58:47Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractIntroduction: Concomitant use of drugs in the same or different indications can sometimes lead to undesirable interactions. The prevalence of drug interactions is high in cancer patients. In this study, we aimed to determine the frequency and clinical severity of drug interactions in outpatient lung cancer patients. Methods: The drugs used, kidney and liver blood analysis results of 160 outpatient lung cancer patients over the age of 18 who received chemotherapy between October 2020 and July 2021 were evaluated. The Lexi-Interact online database was used to identify the types of clinically significant drug interactions, frequently interacting drugs, and clinical outcomes predicted by the databases. Results: The average number of drugs per patient was 4.2 +/- 2.3. It was determined that there was a relationship between multi-drug use and comorbidity, and the number of drugs used increased as the number of diagnoses increased. A relationship was also found between potential drug-drug interactions (pDDI), which we observed in 52.5% of the patients, and the number of drugs used and age. The most common clinically significant C (36.9%), D (16.9%) and X (10.6%) type pDDI were detected between conventional paclitaxel-hydrochlorothiazide, conventional paclitaxel-carboplatin, and ipratropium-tiotropium, respectively. Conclusions: The use of frequently interacting drugs in outpatient lung cancer patients can lead to pDDI. In these patients, the application of therapy by observing the drug-drug interaction may improve the quality of life.
dc.identifier.doi10.1159/000538742
dc.identifier.endpage236
dc.identifier.issn0031-7012
dc.identifier.issn1423-0313
dc.identifier.issue4en_US
dc.identifier.pmid38583427
dc.identifier.scopus2-s2.0-85196730120
dc.identifier.scopusqualityQ2
dc.identifier.startpage231
dc.identifier.urihttps://doi.org/10.1159/000538742
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14502
dc.identifier.volume109
dc.identifier.wosWOS:001202131400001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherKarger
dc.relation.ispartofPharmacology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectadverse reaction
dc.subjectchemotherapy
dc.subjectcomorbidity
dc.subjectmulti-drug use
dc.subjectpharmacovigilance
dc.subjectpolypharmacy
dc.titlePotential drug-drug interactions in outpatient lung cancer patients in a university hospital
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu